Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

Now Viewing

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

In this episode, experts begin outlining how bispecific antibodies work in multiple myeloma. Panelists explain that these agents are designed to bring T cells into close proximity with myeloma cells by binding simultaneously to a tumor antigen and to CD3 on T cells. This interaction activates the patient’s own immune system to directly kill malignant plasma cells. Experts emphasize that bispecifics provide an off-the-shelf immunotherapeutic option that does not require individualized manufacturing, positioning them as an important complement to cellular therapies. They also highlight that different bispecific targets, such as BCMA and GPRC5D, expand available mechanisms for overcoming resistance and allow for tailored sequencing strategies. Overall, the discussion underscores that the unique mechanism of bispecific antibodies offers a potent and accessible way to engage the immune system in patients with relapsed or refractory disease.